Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months for Tuberculosis Preventive Treatment: A Randomized Controlled Study in China

NCT02430259 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT02430259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02430259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months for Tuberculosis Preventive Treatment: A Randomized Controlled Study in China
Lead sponsor
Huashan Hospital
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2015
Completion date
June 30, 2018
Enrollment
566 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

silicosis, tuberculosis